These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38866553)

  • 1. Cardiovascular Adverse Events Associated with Tumor Necrosis Factor-Alpha Inhibitors: A Real-World Pharmacovigilance Analysis.
    Ma J; Cai J; Chen H; Feng Z; Yang G
    J Atheroscler Thromb; 2024 Jun; ():. PubMed ID: 38866553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor Necrosis Factor-Alpha Therapy and Hypoglycemia: A Real-World Pharmacovigilance Analysis.
    Zhou Y; Xie W; Wang L; Zhu X; Li J; Liu L; Zhu S; Wang L
    Drug Saf; 2022 Sep; 45(9):951-959. PubMed ID: 35857191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological disorders following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis.
    Zhao Y; Li Z; Zhang K; Wang N
    Expert Opin Drug Saf; 2024 Aug; 23(8):1041-1048. PubMed ID: 38769926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database.
    Béné J; Moulis G; Auffret M; Lefevre G; Coquerelle P; Coupe P; Péré P; Gautier S
    Rheumatology (Oxford); 2014 Aug; 53(8):1465-9. PubMed ID: 24681837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
    Chen W; Cai P; Zou W; Fu Z
    Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Risk of Glioblastoma with TNF Inhibitors.
    Guo M; Luo H; Samii A; Etminan M
    Pharmacotherapy; 2016 Apr; 36(4):449-54. PubMed ID: 26931498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.
    Mendes D; Alves C; Batel-Marques F
    J Clin Pharm Ther; 2014 Jun; 39(3):307-13. PubMed ID: 24635532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database.
    Pauline O; Robert M; Bernardeau C; Hlavaty A; Fusaroli M; Roustit M; Cracowski JL; Khouri C
    BioDrugs; 2023 Sep; 37(5):699-707. PubMed ID: 37278971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021.
    Wang Y; Cui C; Ren X; Dong X; Cui W
    Front Cardiovasc Med; 2022; 9():988013. PubMed ID: 36312283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
    Huang J; Cai J; Ye Q; Jiang Q; Lin H; Wu L
    BMJ Open; 2023 Aug; 13(8):e071456. PubMed ID: 37536976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of signal detection of tumour necrosis factor-α inhibitors using the Korea Adverse Events Reporting System Database, 2005-2016.
    Ha D; Lee SE; Song I; Lim SJ; Shin JY
    Clin Rheumatol; 2020 Feb; 39(2):347-355. PubMed ID: 31673980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.
    Goldman A; Raschi E; Cukierman-Yaffe T; Dankner R; Shouval R; Shechter M; Ben-Zvi I; Gerstein HC; Maor E
    Eur J Prev Cardiol; 2022 Jul; 29(9):1334-1342. PubMed ID: 34897409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Nonmelanoma Skin Cancers, Melanoma, and Merkel Cell Carcinoma with Dermatologic Medications: A Case-Control Pharmacovigilance Study of the FDA Adverse Events Reporting System.
    Jedlowski PM
    Dermatology; 2023; 239(5):694-699. PubMed ID: 37054693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
    Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
    Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
    Wang Y; Cui C; Deng L; Wang L; Ren X
    Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy Recommendations Solely Based on Preclinical Evidence Should Be Integrated with Real-World Evidence: A Disproportionality Analysis of Certolizumab and Other TNF-Alpha Inhibitors Used in Pregnant Patients with Psoriasis.
    Gaio M; Vastarella MG; Sullo MG; Scavone C; Riccardi C; Campitiello MR; Sportiello L; Rafaniello C
    Pharmaceuticals (Basel); 2024 Jul; 17(7):. PubMed ID: 39065754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
    Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
    Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
    Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
    Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.